CD14 and glioblastoma: A decrease in CD11c+ CD14+ CD16+ HLA-DR high monocytes, accompanied by a significant increase in overall OS, was observed in recurrent glioblastoma after post-surgical Pembrolizumab, but only in patients that had also received neoadjuvant anti-PD-1 immunotherapy before surgery [9].